Tokyo, Feb. 3 -- UMIN Clinical Trials Registry (UMIN-CTR) received information related to the study (UMIN000060555) titled 'Age-related progression of clinical symptoms and the importance of early intervention in 100 heterozygous females with Fabry disease' on Feb. 2.
Study Type:
Observational
Primary Sponsor:
Institute - Nagoya Central Hospital
Condition:
Condition - Fabry disease
Classification by malignancy - Others
Genomic information - NO
Objective:
Narrative objectives1 - This study aimed to analyze the correlation between clinical characteristics and aging in 100 heterozygous females with Fabry disease.
Basic objectives2 - Others
Eligibility:
Age-lower limit - Not applicable
Age-upper limit - Not applicable
Gender - Female
Key inclusion criteria - Female patients with Fabry disease were enrolled in three groups based on their age at first diagnosis: Group 1 (under 29 years old), Group 2 (30 to 49 years old), and Group 3 (over 50 years old).
Key exclusion criteria - excluding those with the E66Q mutation
Target Size - 100
Recruitment Status:
Recruitment status - No longer recruiting
Date of protocol fixation - 2018 Year 12 Month 01 Day
Date of IRB - 2019 Year 01 Month 09 Day
Anticipated trial start date - 2019 Year 02 Month 01 Day
Last follow-up date - 2026 Year 02 Month 02 Day
To know more, visit https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000069150
Disclaimer: Curated by HT Syndication.
